EternaLab is building the operating system for human longevity. We are opening strategic equity participation to a select group of visionary investors who understand that the next trillion-dollar market is not AI alone — it is the intersection of AI and human biology.
The global longevity economy is projected to reach $610 billion by 2030 and $1.2 trillion by 2035. Yet there is no single platform that connects the entire longevity value chain: data, protocols, community, and commerce.
EternaLab is that platform. We are not building another health app. We are creating the infrastructure layer for evidence-based human optimization — the Bloomberg Terminal of longevity.
Founded by a double board-certified surgeon (Germany + Spain). Not influencers — physicians. This is our regulatory moat in European markets.
2,847 research papers indexed. Every protocol graded A through D. No other platform has this level of scientific rigor. This is our IP moat.
The more data users input, the smarter their protocols become. Switching costs increase exponentially. This is our data moat.
Users share protocols, validate results, and create content. The platform improves without incremental cost. Network effects compound.
SaaS subscriptions (€149–€799/mo), supplement commerce (40% margins), B2B licensing to clinics, and data insights — four revenue engines from day one.
Launching in Germany (strongest health-tech regulatory framework in Europe), expanding to DACH, then US. Regulatory compliance is our barrier to entry.
Source: Longevity Technology, Grand View Research, McKinsey Health 2030 Report
“I built EternaLab because I saw the same problem in longevity that I see in surgery: the gap between what science knows and what people actually do. This platform bridges that gap.”
— Alejandro Marti, MD
EternaLab GmbH (in formation). German limited liability company registered in Nürnberg.
€500,000. This ensures aligned, committed partners — not passive capital.
60% product & engineering. 20% market expansion (DACH → US). 15% regulatory & IP. 5% operations.
Board seat for investments above €1M. Quarterly reporting. Full financial transparency.
If you are a qualified investor with a thesis on longevity, health-tech, or the intersection of AI and biology — we would like to hear from you. This is not a pitch. It is a conversation between people who see the same future.